Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$6.13 +0.5%	$4.71	$2.94 ▼ $10.25	$341.69M	3.05	143,822 shs	148,403 shs
PROK ProKidney	$3.15 -10.5%	$1.33	$0.46 ▼ $7.13	$922M	1.26	3.62 million shs	6.55 million shs
TNXP Tonix Pharmaceuticals	$46.91 -0.6%	$35.20	$6.76 ▼ $130.00	$345.13M	2.05	1.00 million shs	1.48 million shs
VHAQ Viveon Health Acquisition	$11.00	$11.00	$0.00 ▼ $12.48	$62.26M	-0.1	12 shs	99 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+0.49%	+13.52%	+29.05%	+61.32%	-3.77%
PROK ProKidney	-10.51%	-30.62%	+352.39%	+298.28%	+36.96%
TNXP Tonix Pharmaceuticals	-0.59%	+14.78%	+36.68%	+198.60%	-21.29%
VHAQ Viveon Health Acquisition	0.00%	0.00%	0.00%	0.00%	+10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FHTX Foghorn Therapeutics	1.426 of 5 stars	3.6	0.0	0.0	0.0	0.6	1.7	0.6
PROK ProKidney	3.5415 of 5 stars	3.2	4.0	0.0	0.0	3.8	3.3	0.6
TNXP Tonix Pharmaceuticals	2.6513 of 5 stars	3.5	2.0	0.0	0.0	1.3	3.3	0.6
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	97.80% Upside
PROK ProKidney	2.40	Hold	$6.25	98.41% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,147.07% Upside
VHAQ Viveon Health Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VHAQ, PROK, FHTX, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$22.60M	15.12	N/A	N/A	($0.82) per share	-7.48
PROK ProKidney	$80K	11,525.06	N/A	N/A	($3.41) per share	-0.92
TNXP Tonix Pharmaceuticals	$10.09M	34.22	N/A	N/A	$31.82 per share	1.47
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)
VHAQ Viveon Health Acquisition	-$610K	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest VHAQ, PROK, FHTX, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$6.71	N/A	N/A	N/A	$2.60 million	N/A
8/14/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.16	3.16
PROK ProKidney	N/A	10.96	10.96
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
PROK ProKidney	51.59%
TNXP Tonix Pharmaceuticals	82.26%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	7.58%
PROK ProKidney	41.49%
TNXP Tonix Pharmaceuticals	0.03%
VHAQ Viveon Health Acquisition	75.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable
VHAQ Viveon Health Acquisition	2	5.66 million	1.40 million	Not Optionable

VHAQ, PROK, FHTX, and TNXP Headlines

Recent News About These Companies

Viveon Health Acquisition Corp

November 21, 2024 | investing.com

Clearday, Inc. (CLRD)

September 6, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updated

May 3, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success

May 2, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process

February 28, 2024 | finanznachrichten.de

VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS

February 27, 2024 | globenewswire.com

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

February 21, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

December 27, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)

December 22, 2023 | tmcnet.com

San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.

November 13, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)

October 24, 2023 | finance.yahoo.com

VHAQ-R Viveon Health Acquisition Corp.

September 23, 2023 | seekingalpha.com

Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation

September 15, 2023 | marketwatch.com

VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION

September 15, 2023 | finance.yahoo.com

Viveon Healthcare Increases Consideration Offered to Clearday Shareholders

September 5, 2023 | finance.yahoo.com

SPAC Viveon ups merger consideration for Clearday to $500M

August 29, 2023 | msn.com

Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement

August 29, 2023 | finance.yahoo.com

VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING

April 25, 2023 | finance.yahoo.com

Viveon Health Acquisition Corp. (VHAQ-RT)

April 18, 2023 | finance.yahoo.com

(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market

April 12, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VHAQ, PROK, FHTX, and TNXP Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$6.13 +0.03 (+0.49%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.14 +0.01 (+0.16%)

As of 07/18/2025 04:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ProKidney NASDAQ:PROK

$3.15 -0.37 (-10.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.04 (+1.43%)

As of 07/18/2025 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tonix Pharmaceuticals NASDAQ:TNXP

$46.91 -0.28 (-0.59%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$47.35 +0.44 (+0.94%)

As of 07/18/2025 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Viveon Health Acquisition NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time